Concourse Financial Group Securities, Inc. Ayala Pharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	N/A
Q2 2024 Jul 23, 2024	BUY	N/A
Q1 2024 Apr 30, 2024	BUY	N/A
Q4 2023 Feb 07, 2024	BUY	N/A
Q3 2023 Oct 30, 2023	BUY	N/A
Q3 2023 Oct 25, 2023	BUY	N/A
Q2 2023 Aug 10, 2023	BUY	N/A
Q1 2023 May 15, 2023	BUY	$0.0 - $0.56 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.38 - $0.71 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.82 - $1.97 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.99 - $4.15 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.5 - $9.11 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$8.32 - $12.45 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$8.13 - $14.09 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$9.2 - $11.3 $0 - $0
Q1 2021 May 13, 2021	BUY	$10.72 - $22.0 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$9.67 - $13.5 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$8.8 - $14.55 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$10.0 - $15.92 $0 - $0

Others Institutions Holding AYLA

# of Institutions

Shares Held

Call Options Held

Put Options Held

View Full List

About Ayala Pharmaceuticals, Inc.

Ticker AYLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,833,300
Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinic...

More about AYLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account